SCHEMBL3700780

SCHEMBL3700780

FC1(F)Oc2ccc(-c3nnc(Nc4ccc(Oc5ccnc6ccsc56)cc4)c4ccccc34)cc2O1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 3/20 0.42
KDM4E B2RXH2 1/20 0.42
USP2 O75604 1/20 0.42
PPARG P37231 1/20 0.42
RECQL P46063 1/20 0.42
BLM P54132 1/20 0.42
NCOA2 Q15596 1/20 0.42
NCOA1 Q15788 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
MET P08581 4/20 0.41
ENPP3 O14638 1/20 0.40
CA2 P00918 1/20 0.40
CA9 Q16790 1/20 0.40
AURKA O14965 3/20 0.40
AURKB Q96GD4 3/20 0.40
TPX2 Q9ULW0 2/20 0.40
MAPT P10636 5/20 0.39
LMNA P02545 1/20 0.39
KMT2A Q03164 2/20 0.39
TP53 P04637 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3699216 0.87 MAPT (0.48) POLBKDM4EUSP2PPARGRECQL
SCHEMBL3699715 0.85 POLB (0.52) POLBKDM4EUSP2PPARGRECQL
SCHEMBL3707651 0.85 PDE10A (0.44) POLBKDM4EUSP2PPARGRECQL
SCHEMBL2209159 0.83 KDR (0.50) POLBKDM4EUSP2PPARGRECQL
SCHEMBL3707198 0.83 AURKA (0.51) POLBKDM4EUSP2PPARGRECQL
SCHEMBL15663346 0.83 MAPT (0.44) POLBKDM4EUSP2PPARGRECQL
SCHEMBL3705713 0.78 AURKA (0.61) POLBKDM4EUSP2PPARGRECQL
SCHEMBL15663306 0.75 KDR (0.39) POLBENPP3CA2CA9AURKA
SCHEMBL3699432 0.72 MAPT (0.48) POLBKDM4EUSP2TDP1AURKA
SCHEMBL15663354 0.72 KDM4E (0.46) POLBKDM4EUSP2PPARGRECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120122847-A1 AURORA KINASE MODULATORS AND METHOD OF USE AMGEN INC. (US) 2012-05-17 US claimed
EP-2137177-B1 AURORA KINASE MODULATORS AND METHOD OF USE AMGEN INC (US) 2014-05-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120122847-A1 AURORA KINASE MODULATORS AND METHOD OF USE AURKC, AURKA, CDK1 POLB 1671/4885KDM4E 1131/4885USP2 3435/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.